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1. Introduction 2. Materials and methods 
l-O-Alkyl-2-O.acetyl-sn-glycero3-phosphocholine 
(AAGPC or 14.alkyl-2-@acetyl-GPC), platelet-acti- 
vating factor (PAF) [l-3], activates platelets and 
neutrophils (PMN) of rabbits and humans [1,3-81 
and is antihypertensive in rats [9]. Analogs of AAGPC 
in which the acetyl group is replaced by an &thy1 or 
O-methyl group are biologically active [4,1 O-l 11. 
Since the 2aethyl analog (l-&lkyl-2X&$hyl-GPC) 
is more active, we selected it earlier to probe the 
mechanism of action of AAGPC. Although the 
2aethyl analog is somewhat less active (20-40.fold) 
than AAGPC, it elicits identical responses [4,5] and 
selectively cross-desensitizes PMN to the action of 
AAGPC [5] and thus appears to act through the same 
mechanism. These studies provide evidence that 
AAGPC does not require transfer of its acetyl group 
to a protein or other cellular component for the 
expression of activity. However, as has been pointed 
out [ 111, some cells contain an oxidative alkyl cleav- 
age system [121 that possibly could remove the 
2Uethyl group as an aldehyde and form 1 O-alkyl- 
2-lyso-GPC, which might then be acetylated to form 
AAGPC. Here, to further investigate the mechanism 
of action of AAGPC, we have prepared and tested 
analogs that contain nonhydrolyzable alkyl groups at 
the 2-position. The most active of these is the n-propyl 
derivative, which aggregates platelets at 6 nM. 
2.1. Synthesis of the 2dlkyl analogs of AAGPC (rac- 
I-O-hexadecyl-2-alkyl-3Ophosphorylcholine- 
propane) 
The appropriate alkyl bromide (n-propyl, isopropyl, 
or isobutyl) was reacted with diethylmalonate in a 
standard malonic ester synthesis to produce predomi- 
nately mono-alkylation. The product was reduced 
with lithium aluminum hydride to give the corre- 
sponding 2-alkyl-1,3-propanediol, which was reacted 
as in [lo] with hexadecyl bromide to give predomi- 
nately the monoether, 1 XXhexadecyl-2.alkyl-3-prop- 
anol. After purification by column chromatography 
on Silica Gel 60 (E.M. Merk), the 3.propanol deriva- 
tives were converted to their corresponding phos- 
phorylcholines as in [ 131. The structure of each of 
the products in the sequence l ading up to the intro- 
duction of the phosphocholine group was confirmed 
by infrared and nuclear magnetic resonance spectros- 
copy. The isobutyl and isopropyl compounds were 
monitored for the presence, and the n-propyl com- 
pounds for the absence of the gem-dimethyl groups. 
The final products were purified by thin-layer chro- 
matography and had RF-vahies the same or slightly 
higher than AAGPC (Silica gel H; chloroform:metha- 
nol:acetic acid:water, 50:25:8:4, by vol.). In addition 
there was a 1: 1 ratio of P/N in each of the analogs. 
Each of the analogs gave molecular (M) and (M + 1) 
ions by desorptive chemical ionization mass pectrom- 
etry using methane as the ionizing gas. In addition 
there were characteristic fragments for each of the 
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compounds. Details of the synthesis of these analogs, 
confirmation of their structure and their complete 
spectral characteristics will be published later. AAGPC 
was prepared from choline-linked plasmalogens of beef 
heart [4]. Concentrations of all analogs were deter- 
mined by measuring lipid phosphorus [ 141. 
2.2. Prepare tion of cells and bioassays 
Rabbit platelets and peritoneal PMN were isolated 
and their aggregation response assayed as in [4]. The 
PMN contained <5 platelets/100 PMN. Human PMN 
were isolated and their degranulation measured as in 
[5]; these leukocyte preparations were 98% PMN and 
contained <2 platelets/100 cells. AAGPC and analogs 
were added to cells in small volumes (5-50 /.dl/ml) of 
bovine serum albumin-containing buffer as in [4]. 
AAGPC and the analogs were assayed in vivo by 
intravenous infusion over 20 s into a femoral vein of 
adult New Zealand rabbits. Blood samples were taken 
from a femoral artery at selected times and platelets 
and PMN counted. 
3. Results 
The following analogs of PAF were prepared and 
tested: 
H,C-0-(CH,),,CH, 
I 
CH,CH,CH,-C-H 
I P 
H,C-0-l;-OCH,CHzN(CH,), 
0- 
2-n-Propyl-PAF 
YH3 I 
CH,CHCH,+H 
I :: 
H,C-0-y-OCH,CH;N(CH& 
O- 
2-Isobutyl-PAF 
Volume 141, number 1 FEBS LETTERS May 1982 
H,C-0-(CH,),,CH, 
YH3 I 
CH,CH-C-H 
I :: 
H,C-0-P-OCH,CH;N(CH,), 
O- 
2-Isopropyl-PAF 
2-n-propyl-PAF 
10-7M 
10-8M 
10-gM 
24sobutyLPAF 
2-isopropyl-PAF 
Fig.1. Aggregation of rabbit platelets in response to analogs 
of PAF. Rabbit platelets were suspended at 2.5 X lO’/ml in 
Tyrode’s-gelatin containing Ca2+ and were incubated with 
stirring at 1000 rev./mm Aggregation was followed by mea- 
suring increased light transmission; the upper tracings repre- 
sent a maximum increase of 60% in transmission and 2 min 
from the point of addition of the analogs, indicated by the 
arrows. Final concentrations of the analogs are indicated for 
each tracing. 
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The aggregation of rabbit platelets in response to 
the analogs is shown in fig.1. The 2-n-propyl analog 
was most active whereas the 2-isopropyl analog 
showed little activity even at lo-’ M. 
The in vitro aggregation of rabbit PMN in response 
to 2-n-propyl-PAF is shown in fig.2C; PMN responded 
to levels of <lo-’ M. The effects of 2-n-propyl-PAF 
administered intravenously to rabbits are also shown 
in tig.2. The disappearance of platelets and PMN from 
circulation following administration of the analog is 
similar to that elicited by AAGPC. 
Activities of the analogs and AAGPC are compared 
in table 1. As with all responses, the 2-n-propyl-PAF 
was more active than the 2-isobutyl-PAF in the degran- 
ulation of human PMN; 2-isopropyl-PAF elicited little 
response in any instance at <l PM. 
4. Discussion 
The most active of the analogs tested was the 
2-n-propyl-PAF. All the analog preparations were 
racemic, whereas the 1 -O-alkyl-2-acetyl-GPC tested 
was the pure sn-glycero3-phosphocholine isomer. 
Based on [3,10,15] only one of the enantiomers i
presumed to be active; if the potencies observed are 
adjusted accordingly, the activity of the 2-n-propyl 
analog is similar to the activity of the 2Uethyl 
Fig.2. Effect of n-propyl-PAF on platelet and neutrophil 
counts after injection into rabbits and the in vitro aggregation 
of rabbit neutrophils. For the in vivo studies, analogs were 
administered at the doses shown and cells counted as in sec- 
tion 2. The aggregation of PMN is shown as the large particle 
percentage of PMN suspensions after addition of n-propyl 
PAF. Final concentrations of the analog are given. PMN were 
incubated in Hank’s buffer containing 1.4 mM Ca*+ and 
0.7 mM Mgz+ for 5 min (37°C) before challenge. 
Table 1 
Relative potencies of PAF and its analogs in various assays 
Assay Analog (molarity or dose/kg) 
l-O-Alkyl- 
2-acetyl-CPC 
n-Propyl-PAF Isobutyl-PAF Isopropyl-PAF 1-O-Alkyl- 
2-Iyso-GPC 
Platelet aggregation 
(rabbit) 5 X lo-” M 4 x 1O-9 M 6 X 1O-8 M >10-6 M >10-6 M 
Neutrophil aggregation 
(rabbit) 4 X 1O-9 M 4 x lo-’ M 4 X lo+ M >10-6 M >10-6 M 
Neutrophil degranulation 
(human) 3 X lo+ M 4 x lo-’ M 2 x 1O-6 M >10-6 M >10-6 M 
In vivo neutropenia 
(rabbit) 0.8 pg/kg 100 rg/kg n.d. >l mg/kg >1 mg/kg 
In vivo thrombocytopenia 
(rabbit) 0.3 rg/kg 50 &kg n.d. >1 mg/kg >l mg/kg 
For in vitro assays, cells were suspended with varying doses of stimulus (as described in fig.l,2 and section 2) and the ensuing 
response measured. For in vivo assays, rabbits were infused with varying doses of stimulus. For all assays, responses were plotted 
against the Log of dose. The concentration (M) or dose of agent that caused 50% of the maximal platelet or neutrophil aggregation 
response, net release of 5% lysozyme (for degranulation), or depression of the number of circulating cells by 50% of preinfusion 
values (for neutropenia and thrombocytopenia) were extrapolated; n.d., not determined 
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analog in [4] and much more active than the 1 -U-alkyl- 
2-lyso-GPC (table 1). The 2-n-propyl-PAF has very 
low antihypertensive activity in rats (in preparation) 
suggesting it may be possible to separate the anaphy- 
lactic and antihypertensive effects of AAGPC. 
The spatial dimensions of the 2-alkyl group in the 
analogs appear critical for activity since the 2-n-propyl 
analog is active whereas the 2-isopropyl analog is not. 
Similar propanediol analogs containing either no alkyl 
group at the 2-position [ 1 l] or gem-dimethyl groups 
[ 111 are inactive, and that the substitution of the 
acetyl group of 1-O-alkyl-2-acetyl-GPC with chains 
longer than propionyl groups leads to loss of activity 
[1,16]. Furthermore, the 2-&thy1 derivative is more 
active than the 20methyl derivative [lo]; thus there 
appear to be strict steric constraints on groups at the 
2-position. This sharply restricted range of size fits a 
model in which activity is mediated by a receptor 
requiring a specific steric fit for activation. 
The activities of the 2-n-propyl and 2-isobutyl ana- 
logs cannot be attributed to activation by the O-alkyl 
cleavage system. It was warned that contamination by 
AAGPC can be a serious source of error [ 161. This 
was ruled out here and in [4] (on 1-O-alkyl-2_Oethyl- 
GPC) by mild saponification [ 171, which removes the 
acetyl group of AAGPC but not the phosphocholine 
group; the treatment reduced the activity of AAGPC 
by >lOOO-fold but had virtually no effect on the 
activity of the 2-n-propyl analog. In contrast to [ 161, 
we conclude that appropriate non-ester groups can 
replace the shortchain of AAGPC with retention of 
activity. These findings strengthen our evidence [3,4] 
that in platelets and PMN transfer of the acetyl group 
is not required for activity of AAGPC. 
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